ADBiotech Co., Ltd. (KOSDAQ:179530)

ADBiotech Statistics

Total Valuation

ADBiotech has a market cap or net worth of KRW 41.01 billion. The enterprise value is 52.96 billion.

Market Cap	41.01B
Enterprise Value	52.96B

Important Dates

The next estimated earnings date is Thursday, November 13, 2025.

Earnings Date	Nov 13, 2025
Ex-Dividend Date	n/a

Share Statistics

ADBiotech has 12.66 million shares outstanding. The number of shares has increased by 7.67% in one year.

Current Share Class	12.66M
Shares Outstanding	12.66M
Shares Change (YoY)	+7.67%
Shares Change (QoQ)	+18.63%
Owned by Insiders (%)	19.84%
Owned by Institutions (%)	11.65%
Float	8.71M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	3.24
PB Ratio	14.00
P/TBV Ratio	10.12
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-7.26
EV / Sales	4.18
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-11.61

Financial Position

The company has a current ratio of 0.63, with a Debt / Equity ratio of 5.53.

Current Ratio	0.63
Quick Ratio	0.36
Debt / Equity	5.53
Debt / EBITDA	n/a
Debt / FCF	-3.55
Interest Coverage	-4.56

Financial Efficiency

Return on equity (ROE) is -208.07% and return on invested capital (ROIC) is -14.32%.

Return on Equity (ROE)	-208.07%
Return on Assets (ROA)	-11.01%
Return on Invested Capital (ROIC)	-14.32%
Return on Capital Employed (ROCE)	-55.27%
Revenue Per Employee	214.80M
Profits Per Employee	-123.57M
Employee Count	59
Asset Turnover	0.57
Inventory Turnover	3.11

Taxes

Income Tax	-192.54M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +1.05% in the last 52 weeks. The beta is 1.42, so ADBiotech's price volatility has been higher than the market average.

Beta (5Y)	1.42
52-Week Price Change	+1.05%
50-Day Moving Average	3,325.00
200-Day Moving Average	2,574.58
Relative Strength Index (RSI)	47.59
Average Volume (20 Days)	844,611

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, ADBiotech had revenue of KRW 12.67 billion and -7.29 billion in losses. Loss per share was -740.81.

Revenue	12.67B
Gross Profit	5.05B
Operating Income	-3.93B
Pretax Income	-7.83B
Net Income	-7.29B
EBITDA	-2.92B
EBIT	-3.93B
Loss Per Share	-740.81

Balance Sheet

The company has 3.08 billion in cash and 16.19 billion in debt, giving a net cash position of -13.11 billion or -1,036.16 per share.

Cash & Cash Equivalents	3.08B
Total Debt	16.19B
Net Cash	-13.11B
Net Cash Per Share	-1,036.16
Equity (Book Value)	2.93B
Book Value Per Share	344.57
Working Capital	-5.74B

Cash Flow

In the last 12 months, operating cash flow was -4.31 billion and capital expenditures -254.88 million, giving a free cash flow of -4.56 billion.

Operating Cash Flow	-4.31B
Capital Expenditures	-254.88M
Free Cash Flow	-4.56B
FCF Per Share	-360.57

Margins

Gross margin is 39.88%, with operating and profit margins of -31.01% and -57.53%.

Gross Margin	39.88%
Operating Margin	-31.01%
Pretax Margin	-61.82%
Profit Margin	-57.53%
EBITDA Margin	-23.00%
EBIT Margin	-31.01%
FCF Margin	n/a

Dividends & Yields

ADBiotech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-7.67%
Shareholder Yield	-7.67%
Earnings Yield	-17.78%
FCF Yield	-11.13%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on May 26, 2021. It was a forward split with a ratio of 3.

Last Split Date	May 26, 2021
Split Type	Forward
Split Ratio	3

Scores

ADBiotech has an Altman Z-Score of -1.4 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-1.4
Piotroski F-Score	4